98%
921
2 minutes
20
Purpose: During the radiation treatment planning process, one of the time-consuming procedures is the final high-resolution dose calculation, which obstacles the wide application of the emerging online adaptive radiotherapy techniques (OLART). There is an urgent desire for highly accurate and efficient dose calculation methods. This study aims to develop a dose super resolution-based deep learning model for fast and accurate dose prediction in clinical practice.
Method: A Multi-stage Dose Super-Resolution Network (MDSR Net) architecture with sparse masks module and multi-stage progressive dose distribution restoration method were developed to predict high-resolution dose distribution using low-resolution data. A total of 340 VMAT plans from different disease sites were used, among which 240 randomly selected nasopharyngeal, lung, and cervix cases were used for model training, and the remaining 60 cases from the same sites for model benchmark testing, and additional 40 cases from the unseen site (breast and rectum) was used for model generalizability evaluation. The clinical calculated dose with a grid size of 2 mm was used as baseline dose distribution. The input included the dose distribution with 4 mm grid size and CT images. The model performance was compared with HD U-Net and cubic interpolation methods using Dose-volume histograms (DVH) metrics and global gamma analysis with 1%/1 mm and 10% low dose threshold. The correlation between the prediction error and the dose, dose gradient, and CT values was also evaluated.
Results: The prediction errors of MDSR were 0.06-0.84% of D indices, and the gamma passing rate was 83.1-91.0% on the benchmark testing dataset, and 0.02-1.03% and 71.3-90.3% for the generalization dataset respectively. The model performance was significantly higher than the HD U-Net and interpolation methods (p < 0.05). The mean errors of the MDSR model decreased (monotonously by 0.03-0.004%) with dose and increased (by 0.01-0.73%) with the dose gradient. There was no correlation between prediction errors and the CT values.
Conclusion: The proposed MDSR model achieved good agreement with the baseline high-resolution dose distribution, with small prediction errors for DVH indices and high gamma passing rate for both seen and unseen sites, indicating a robust and generalizable dose prediction model. The model can provide fast and accurate high-resolution dose distribution for clinical dose calculation, particularly for the routine practice of OLART.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639714 | PMC |
http://dx.doi.org/10.1016/j.zemedi.2022.10.006 | DOI Listing |
Res Vet Sci
September 2025
Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand. Electronic address:
Carprofen (CAR) is an NSAID commonly used in veterinary medicine that preferentially inhibits cyclooxygenase-2 (COX-2), thereby mitigating inflammation and pain while minimizing adverse effects linked to cyclooxygenase-1 (COX-1) inhibition. This study characterizes the pharmacokinetics of CAR in Siamese crocodiles (Crocodylus siamensis) and was conducted at an ambient temperature range of 27-30 °C following single intravenous (IV) or intramuscular (IM) administration at 2 mg/kg, and IM administration at 4 mg/kg. Plasma concentrations were determined using a validated high-performance liquid chromatography method with ultraviolet detection (HPLC-UV).
View Article and Find Full Text PDFMol Ther Methods Clin Dev
June 2025
Université Paris-Saclay, University Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France.
Pompe disease is a glycogen storage disorder caused by mutations in the acid α-glucosidase (GAA) gene, leading to reduced GAA activity and glycogen accumulation in heart and skeletal muscles. Enzyme replacement therapy with recombinant GAA, the standard of care for Pompe disease, is limited by poor skeletal muscle distribution and immune responses after repeated administrations. The expression of GAA in muscle with adeno-associated virus (AAV) vectors has shown limitations, mainly the low targeting efficiency and immune responses to the transgene.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
June 2025
Shanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.
View Article and Find Full Text PDFComput Struct Biotechnol J
August 2025
Institut de Recherche en Cancérologie de Montpellier (IRCM), Équipe Labellisée Ligue Contre le Cancer, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
Digital twins (DTs) are emerging tools for simulating and optimizing therapeutic protocols in personalized nuclear medicine. In this paper, we present a modular pipeline for constructing patient-specific DTs aimed at assessing and improving dosimetry protocols in PRRT such as therapy. The pipeline integrates three components: (i) an anatomical DT, generated by registering patient CT scans with an anthropomorphic model; (ii) a functional DT, based on a physiologically-based pharmacokinetic (PBPK) model created in SimBiology; and (iii) a virtual clinical trial module using GATE to simulate particle transport, image simulation, and absorbed dose distribution.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Physics, Shi.C., Islamic Azad University, Shiraz, Iran.
Background: Another approach to improve the dose conformity is to use charged particles like protons instead of the conventional X- and γ-rays. Protons exhibit a specific depth-dose distribution which allows to achieve a more targeted dose deposition and a significant sparing of healthy tissue behind the tumor. In particular, proton therapy has, therefore, become a routinely prescribed treatment for tumors located close to sensitive structures.
View Article and Find Full Text PDF